WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016
|
|
- Bathsheba Poole
- 6 years ago
- Views:
Transcription
1 WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS MJFF Third Thursdays Webinar March 17, 2016
2 WHAT WE LL COVER TODAY How is Parkinson s misdiagnosed? How is Parkinson s diagnosed today? Can we use DaTscan to diagnose Parkinson s disease? Why is earlier and more confident diagnosis important? How are scientists working toward more accurate and earlier diagnosis? 2
3 OUR PANELISTS Moderator: Dave Iverson Founding Member, MJFF Patient Council Panelists: Bill Bucklew Executive at Product Development Company in Illinois Diagnosed with Parkinson s in 2012 Danna Jennings, MD Clinical Research Director Institute for Neurodegenerative Disorders Samantha Hutten, PhD Senior Associate Director, Research Programs The Michael J. Fox Foundation 3
4 WRONG/DELAYED DIAGNOSIS IS A PROBLEM IN PARKINSON S CARE AND RESEARCH People with PD diagnosed with other conditions Patients with gait disturbances see more delayed diagnosis than people with tremor 1 Early symptoms may be dismissed as signs of natural aging 2 People without Parkinson s told they have PD Studies show up to 20% of people diagnosed with Parkinson s do not truly have the disease 3 Essential tremor and Alzheimer s disease are among the conditions that can be mistaken for PD 4 Other parkinsonisms such as multiple system atrophy can look like PD 5 4
5 THERE IS NO OBJECTIVE DIAGNOSTIC TEST FOR PARKINSON S DISEASE PD diagnosis is still based primarily on clinical observation. Physicians observe and weigh different factors: 6 Clinical symptoms Tremor, rigidity, slowness Criteria that show it is unlikely PD Normal dopamine system imaging No response to levodopa Medications that may cause motor symptoms 5
6 WHAT ABOUT DATSCAN? Dopamine transporter (DaT) scans visualize dopamine activity in the brain DaTscan can tell if someone has a disease of dopamine loss, but there are others beside Parkinson s (e.g., multiple system atrophy) DaTscan is being used more in research to cut down on enrollment of misdiagnosed volunteers. 3. DaTscan may help test drugs trying to slow or stop early-stage disease (when see most dopamine loss). 8 Image from Cedars-Sinai 6
7 PROPER DIAGNOSIS IS IMPORTANT FOR CARE AND FOR DEVELOPMENT OF NEW THERAPIES The right diagnosis can help patients find the right treatment regimen and plan for the future. Proper diagnosis also is essential for research: 9 Scientists need to observe and learn about Parkinson s from people with the true disease. Testing treatments against Parkinson s in people without PD means successful drugs may look ineffective in trials. Earlier diagnosis would allow for testing of therapies earlier in disease. A population of more confidently diagnosed participants could also allow for smaller, less expensive and quicker studies. 7
8 MEASURING A KEY PROTEIN COULD HELP DIAGNOSE PARKINSON S EARLIER The protein alpha-synuclein clumps together in Parkinson s, which may cause cell loss and symptoms 10 Researchers are working on an imaging agent to visualize alpha-synuclein in the brain 11 Scientists may be able to measure alpha-synuclein outside the brain 12 Separate studies have measured alpha-synuclein in skin, blood, spinal fluid and tissue 12 A new study looks at alpha-synuclein across the body in one person 13 8
9 A RISK MODEL COULD DIAGNOSE OR EVEN PREDICT WHO WILL DEVELOP PARKINSON S Evaluating certain measures together could tell who had PD in a study group and could identify people who may develop PD Genetic risk score 2. Age 3. Sex 4. Family history of neurological disease 5. Smell function Researchers used data from the MJFF-led Parkinson s Progression Markers Initiative to develop this model. 9
10 QUESTIONS & ANSWERS Type your questions in the Q&A box in the middle of your screen. Check the Resource List for more information.
11 PARTICIPATE IN CLINICAL RESEARCH: foxtrialfinder.org WATCH PREVIOUS WEBINARS: michaeljfox.org/webinars
STUDIES TO SLOW OR STOP PARKINSON S DISEASE. MJFF Third Thursdays Webinar October 15, 2015
STUDIES TO SLOW OR STOP PARKINSON S DISEASE MJFF Third Thursdays Webinar October 15, 2015 WHAT WE LL COVER TODAY What are the varied approaches to stop Parkinson s? How can our immune system help fight
More informationDisclaimer. Dialogue with a Patient 3/18/2016
Medical Affairs and Scientific Communications 2016 Annual Forum Dialogue with a Patient Bill Wilkins, Co-Founder, Executive Director, Wilkins Parkinsons Foundation March 21-23 Kissimmee, FL Disclaimer
More informationINTRODUCTION TO FOX TRIAL FINDER. Accelerating Clinical Trial Recruitment Online
INTRODUCTION TO FOX TRIAL FINDER Accelerating Clinical Trial Recruitment Online MJFF WAS FOUNDED WITH CLEAR OBJECTIVES Drive the best Parkinson s disease research Deliver improved therapies and a cure
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationDesigning patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials
1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. Designing
More information2017 Research Year in Review
2017 Research Year in Review Extraordinary trends have been evident in Parkinson s disease (PD) research for the past several years, and 2017 was no exception. The PD drug development pipeline, once stalled
More informationEMERGING TREATMENTS FOR PARKINSON S DISEASE
EMERGING TREATMENTS FOR PARKINSON S DISEASE Katerina Markopoulou, MD, PhD Director Neurodegenerative Diseases Program Department of Neurology NorthShore University HealthSystem Clinical Assistant Professor
More informationWELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW
WELCOME Parkinson s 101 for the Newly Diagnosed Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW Parkinson s Disease 101 Presenter for Today Cari Friedman, LCSW Patient and Family Service
More informationCorporate Medical Policy
Corporate Medical Policy Dopamine Transporter Imaging with Single Photon Emission File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dopamine_transporter_imaging_with_single_photon_emission_computed_tomography
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationWhat are the Latest Treatment Advances in Parkinson disease
What are the Latest Treatment Advances in Parkinson disease Fatta B. Nahab, M.D. Associate Professor of Neurosciences Director, Functional Imaging of Neurodegenerative Disorders Lab Overview Recently approved
More informationClinical Trial Glossary
Clinical Trial Glossary Adverse event An unfavorable change in health that can occur during a clinical trial or study or within a certain time period after. These can range from mild (e.g., nausea) to
More informationDave Iverson: [00:00:30]
Michael J Fox: [00:00:30] [00:01:00] [00:01:30] [00:02:00] [00:02:30] [00:03:00] [00:03:30] This is Michael J. Fox. Thanks for listening to this podcast. Learn more about the Michael J. Fox Foundation's
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationA Four Point Plan for Enhanced Support for Parkinson s Disease In B.C.
A Four Point Plan for Enhanced Support for Parkinson s Disease In B.C. February 14, 2017 Executive Summary More than 13,300 British Columbians live with Parkinson s Disease (PD) and our aging population
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationUPDATE ON RESEARCH IN PARKINSON S DISEASE
UPDATE ON RESEARCH IN PARKINSON S DISEASE Charles H. Adler, M.D., Ph.D. Professor of Neurology Mayo Clinic College of Medicine Co-Principal Investigator Arizona Parkinson s Disease Consortium Arizona Study
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More information2017 Phoenix Clinical Research Fair Program of Events
2017 Phoenix Clinical Research Fair Program of Events From 8:45 a.m. Check-in Second Floor of the Conference Center 8:45 a.m. 1:00 p.m. Trial Exhibition Second Floor of the Conference Center 9:30 a.m.
More informationParkinson s Foundation
Parkinson s Foundation PD ExpertBriefing: Diagnosis PD, Now What? Managing the First Few Years with Parkinson s Led By: Suketu Khandhar, M.D., Medical Director at Kaiser Permanente Northern California
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationNervous System Document Based Questions (DBQ)
Artifact A NFL Players Face Triple the Risk of Neurological Disease MIAMI (CBS Miami) A new report from the Centers for Disease Control and Prevention could break new ground on concussions suffered by
More informationProgram Agenda. 11:45 AM ET Registrants Join the Program Dial-in: (877) Log-in:
Program Agenda Tuesday, January 26, 2016 12:00 PM to 1:00 PM Eastern Time 11:00 AM to 12:00 PM Central Time 10:00 AM to 11:00 AM Mountain Time 9:00 AM to 10:00 AM Pacific Time 11:45 AM ET Registrants Join
More informationWelcome to today s webinar
Welcome to today s webinar We will begin the webinar at 2:00 p.m. Eastern All attendee lines are automatically muted. This webinar is being recorded and will be posted on LBDA s Youtube page. Throughout
More informationPPMI Genetics Cohorts
PPMI Genetics Cohorts Ken Marek PPMI Genetics Kickoff Sept 16, 2013 New York, NY PPMI Genetic Cohort/Registry Symptomatic Neuron Function Prodromal P-PPMI Gen P-PPMI PPMI Diagnosis PPMI- Gen 2 PPMI-Genetics
More informationDVD. Inside. Featuring Michael J. Fox
DVD Inside A guide for patients and families Featuring Michael J. Fox A guide for patients and families Copyright 2013 American Academy of Neurology All Rights Reserved No part of this book may be reproduced
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationWhat is dementia. with Lewy bodies?
What is dementia with Lewy bodies? Contents 03 What is dementia with Lewy bodies? 04 Symptoms 05 Diagnosis 06 Treatments Information in this booklet is for anyone who wants to know more about dementia
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationParkinson s Disease AGE 50, ALTHOUGH IT SOMETIMES OCCURS IN YOUNGER ADULTS. PARKINSON S DISEASE MOST OFTEN DEVELOPS AFTER
Parkinson s Disease Parkinson s, a neurological disorder, affects a person s nervous system, resulting in involuntary tremors, and difficulty with walking, movement and coordination. This disorder is caused
More informationThe Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More informationBehavioral Aspects of Parkinson s Disease
Behavioral Aspects of Parkinson s Disease Joseph H. Friedman, MD Director, Movement Disorders Program Butler Hospital Dept of Neurology Alpert Medical School of Brown University 1 Disclosures Drugs will
More informationTHIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY?
THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY? THURSDAY MARCH 14, 2019 REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA AMERICAN
More informationTreatment of Alzheimer disease and Parkinson disease with CT scans
Professional Engineers Ontario York Chapter Yummy Grill, Vaughan, February 28, 2017 Treatment of Alzheimer disease and Parkinson disease with CT scans Jerry M. Cuttler, DSc, PEng, Cuttler & Associates,
More informationHeadway Victoria Epilepsy and Parkinson s Centre
Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and
More informationParkinson s UK Brain Bank
Parkinson s UK Brain Bank From Brain to Breakthrough Dr George Gveric Manager 19 October 2018 Coordinated approach Donors Relatives Information Reporting Researchers Tissue supply Quality assurance Expertise
More informationParkinson s disease: Can we move in the right direction?
Snapshots of Doctoral Research at University College Cork 2012 Parkinson s disease: Can we move in the right direction? Shane Hegarty Department of Anatomy and Neuroscience, UCC Imagine losing the control
More informationSPEAKING UP ABOUT OFF PERIODS
SPEAKING UP ABOUT OFF PERIODS A doctor discussion guide for people living with Parkinson s Actor portrayal What exactly are OFF periods? OFF periods are when Parkinson s symptoms return between regular
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationParkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. What is Parkinson s Disease?
Parkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationTHE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH. Funding Opportunities
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH Funding Opportunities AGENDA 1. Brief Overview of MJFF Philosophy 2. MJFF Funding Programs 3. How to apply 4. What happens next? 5. Q&A Please feel
More informationChange the size of any window by dragging the lower left corner. Use controls
Early Detection of Parkinson s s Disease Change the size of any window by dragging the lower left corner. Use controls in top right corner to close or maximize each window Use text box at bottom left to
More informationParkinson s Research Program
Parkinson s Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military, and the public
More informationOverview of Parkinson s disease Research at University of Colorado
Overview of Parkinson s disease Research at University of Colorado Brian D. Berman, MD, MS May 12, 2018 University of Colorado Movement Disorders Center Terminology Basic science pure/fundamental scientific
More informationMultiple System Atrophy
Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on
More informationKelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center
Kelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center Disclosures Research support from St. Jude / Abbott Funding National Institutes of Health / NINDS Parkinson Foundation
More informationWhat is dementia with Lewy bodies?
What is dementia with Lewy bodies? Introduction Information in this booklet is for anyone who wants to know more about dementia with Lewy bodies (DLB). This includes people living with DLB, their carers,
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationCognitive Impairment - Parkinson's Disease Foundation (PDF)
Page 1 of 8 Cognitive Impairment Another troublesome symptom of Parkinson s is mild cognitive impairment. Many people with Parkinson s are surprised to find that they feel distracted or disorganized, or
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationGeneral remarks on Neurorejuvenation Spinal Cord Stimulation (SCS) Program Occipital Nerve Stimulation Gamma-knife for Trigeminal Neuralgia
General remarks on Neurorejuvenation Spinal Cord Stimulation (SCS) Program Occipital Nerve Stimulation Gamma-knife for Trigeminal Neuralgia Deep brain Stimulation (DBS) Program Neuromodulation is a field
More informationNeuroimaging and Neurostimulation: Going inside the black box
Neuroimaging and Neurostimulation: Going inside the black box Benzi M. Kluger M.D., M.S. Director, Movement Disorders Center Associate Professor of Neurology & Psychiatry University of Colorado OUTLINE
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationImpact of vitamins & nutrients on neurological function. B-vitamins and aging. Nafisa Jadavji, PhD
Impact of vitamins & nutrients on neurological function B-vitamins and aging Nafisa Jadavji, PhD nafisa.jadavji@carleton.ca Lecture Outline Answer to questions from last class Homocysteine Vitamin B9:
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationSupportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease Ginger S. Johnson, PhD Vice President Defined Health Todd Sherer, PhD Chief Executive
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationreverse parkinsons BAD27E3FE044E25F3F8EBDA3B54333A9 Reverse Parkinsons 1 / 6
Reverse Parkinsons 1 / 6 2 / 6 3 / 6 Reverse Parkinsons Reverse Parkinson's Disease!-Take back your life! Do you want to improve your quality of life, when you have Parkinson's disease? Contrary to the
More informationCase Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background
Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background Heather Benz, Ph.D. FDA Center for Devices and Radiological Health Neurological Degenerative Diseases Neurodegenerative
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationEXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD. Chicago Clinical Research Fair June 11, 2016
EXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD Chicago Clinical Research Fair June 11, 2016 HOW DO WE LEARN MORE ABOUT PARKINSON S DISEASE? Patient-reported data Diagnosis and clinical symptoms
More informationMETHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE
METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE Madrid, 14 de noviembre de 2017 1. THE TEAM AND THE INSTITUTIONS BEHIND
More informationSamantha K. Holden, MD East 17th Avenue Campus Box B185 Aurora, CO Phone:
EDUCATION Samantha K. Holden, MD University of Colorado Anschutz Medical Campus, Colorado Clinical and Translational Sciences Institute, Clinical Sciences Graduate Program, M.S. in Clinical Science. Expected
More informationPD ExpertBriefing: What s in the Parkinson s Pipeline
PD ExpertBriefing: What s in the Parkinson s Pipeline Presented by: David G. Standaert, M.D., Ph.D. Professor of Neurology Director, Center for Neurodegeneration and Experimental Therapeutics University
More informationCAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by:
CAREGIVER SUMMIT The PD You Can't See: Dealing with Non-Motor Symptoms Kaitlyn Roland, PhD Sponsored by: Cognition VS Dementia Memory Executive Function Attention Bradyphrenia Visuospatial Language Hallucinations
More informationBiomedical Technology Research Center 2011 Workshop San Francisco, CA
Diffusion Tensor Imaging: Parkinson s Disease and Atypical Parkinsonism David E. Vaillancourt court1@uic.edu Associate Professor at UIC Departments t of Kinesiology i and Nutrition, Bioengineering, and
More informationANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE
ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE 21 February 217 MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission To accelerate the development
More informationNon-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative
Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationSPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS
PARKINSON S DISEASE SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS THURSDAY, MAY 11, 2017 WELCOME AND INTRODUCTIONS Stephanie Paul Vice President Development and Marketing American Parkinson
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationPD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET
PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask Presented By: Alexander I. Tröster, PhD, ABPP University of North Carolina, Chapel Hill, NC Tuesday, March
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationDate of Referral: Enhanced Primary Care Pathway: Parkinson s Disease
Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:
More informationMJFF S VISION FOR PARTNERING WITH PATIENTS. Sohini Chowdhury The Michael J. Fox Foundation
MJFF S VISION FOR PARTNERING WITH PATIENTS Sohini Chowdhury The Michael J. Fox Foundation OUR SINGLE, URGENT GOAL: CURE PARKINSON S DISEASE MJFF s Mission The Michael J. Fox Foundation is dedicated to
More informationREPURPOSED THERAPIES IN PARKINSON S DISEASE
REPURPOSED THERAPIES IN PARKINSON S DISEASE What Patients and Families Need to Know Rachel Dolhun, MD Vice President, Medical Communications The Michael J. Fox Foundation Repurposing testing drugs often
More informationWhat is Parkinson s disease?
What is Parkinson s disease? 2 credit hour course Parkinson s disease (PD) is a disorder caused by a loss of nerve cells in a small part of the brain called the substantia nigra. This area of nerve cells
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationClinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries
Clinical Differences Among Four Common Dementia Syndromes a program of Morningside Ministries Introduction Four clinical dementia syndromes account for 90% of all cases after excluding reversible causes
More informationSection 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST
4/27/2012 Parkinson's Disease Webinar April 27th, 2012 12:00-1:00 PM EST Presenter: Jon Collins, Manager, Programs and Events, Parkinson Society Central & Northern Ontario Section 1: What is Parkinson
More informationPD AND FALLS J U MALLYA FALLS AWARENESS MEETING
PD AND FALLS J U MALLYA FALLS AWARENESS MEETING 23-09-2016 PD Chronic Progressive neurodegenerative disease Motor system disorder Degeneration of Dopaminergic neurons in Substantia nigra in the midbrain.
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationMOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationPARKINSON S DISEASE OVERVIEW, WITH AN EMPHASIS ON PHYSICAL WELLBEING. Gillian Quinn MISCP, Senior Physiotherapist in Neurology, SVUH
PARKINSON S DISEASE OVERVIEW, WITH AN EMPHASIS ON PHYSICAL WELLBEING Gillian Quinn MISCP, Senior Physiotherapist in Neurology, SVUH PARKINSON'S DISEASE PD is a progressive neurological disease resulting
More informationLatest Methods to Early Detection for Alzheimer's: Cognitive Assessments and Diagnostic Tools in Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/alzheimers-disease-towards-earlier-detection/latest-methods-earlydetection-alzheimers-cognitive-assessments-and-diagnostic-tools-practice/8321/
More informationExecutive Summary
------------------------------------------------------ Executive Summary Vietnam Service, Chemical Exposure and Parkinson s disease (PD) ------------------------------------------------------ Executive
More informationNeurology: Stroke. Former President Reagan. Evaluation of an Infant s Seizures. Traumatic Brain Injury (TBI) 1/13/2014
Neurology: The study of nervous system anatomy, physiology, and pathology, as well as the treatment of its disorders http://www.uni.edu/walsh/neuro99.html Stroke This stroke survivor is going through rehab.
More informationDopamine Transporter Imaging With Single-Photon Emission Computed. Tomography
Dopamine Transporter Imaging With Single-Photon Emission Computed Tomography Policy Number: 6.01.54 Last Review: 9/2018 Origination: 9/2015 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More information